Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia

Miguel Carracedo; Leif Stenke; Anders Franco-Cereceda; Magnus Bäck

doi:10.1016/j.jaccao.2019.12.001

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia

JACC CardioOncol. 2020 Mar 17;2(1):123-126. doi: 10.1016/j.jaccao.2019.12.001. eCollection 2020 Mar.

Authors

Miguel Carracedo¹, Leif Stenke^{1

2}, Anders Franco-Cereceda^{3

4}, Magnus Bäck^{1

2}

Affiliations

¹ Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
² Theme Cancer, Division of Hematology, Karolinska University Hospital, Stockholm, Sweden.
³ Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
⁴ Theme Heart and Vessels, Division of Valvular and Coronary Disease, Karolinska University Hospital, Stockholm, Sweden.

No abstract available

Keywords: BMP, bone morphogenic protein; CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor; VIC, valvular interstitial cell; aortic stenosis; leukemia; nilotinib; tyrosine kinase inhibitor; valvular disease.

Publication types

Review